AP or TP

Phase 2Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

AP or TP is one of 14 small molecule programs targeting Recurrent or Metastatic. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent or MetastaticActive, not recruiting

Recurrent or MetastaticPhase 2

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Recurrent or Metastatic

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

5 2

Lynparza

AstraZeneca

Phase 2

1 3

Paraplatin

AAvyxa

Phase 2

6 4

Taxotere

AAvyxa

Phase 2

1 5

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 6

Inlyta

PPrism Pharmaceuticals

Phase 2

1 7

FH-006

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 8

Sacituzumab Tirumotecan

Merck & Co.

Phase 2

1 9

AK104

AAkeso

Phase 2

1 10

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recurrent or Metastatic1 trial

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT05020457·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AP or TP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AP or TP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AP or TP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

AP or TP

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Recurrent or Metastatic1 trial

References

Drug Info

Quick Facts

Related News